Mounjaro 30mg: the question, the facts, and your real options

Why 30mg keeps appearing, and why you should treat it as a red flag

The misconception that 30mg is a higher, more effective tier of Mounjaro circulates on social media and in certain online marketplaces. It almost certainly stems from confusion with compounded or reconstituted tirzepatide products, which are sometimes expressed in total-vial quantities rather than per-dose strengths. A 30mg vial label, for example, might indicate that a multi-dose vial contains enough powder for several injections at various concentrations, not that a single dose of 30mg exists or is appropriate.

That framing matters because unlicensed compounded tirzepatide sits outside the MHRA's approval process. The regulator has no visibility of its purity, sterility or actual concentration. Reconstitution of peptide powders carries genuine risks: dosing errors, contamination and storage failures are all documented problems. If you've been trying to research how to reconstitute a 30mg tirzepatide preparation, the honest answer is that this is not a process a patient should be carrying out at home with an unlicensed product.

The MHRA's enforcement work through 2025 included raids on unlicensed UK sites producing counterfeit tirzepatide pens, with roughly 20 million doses of illegally traded weight-loss medicines (valued at around £45 million) seized across that year. The pattern is consistent: products sold outside the licensed supply chain carry risks that no dose optimisation strategy can offset. If the product isn't genuine, the dose printed on the label is irrelevant.

What Mounjaro's licensed dose range actually covers, and how far it goes

Licensed Mounjaro starts at 2.5mg. That first strength is a settling-in dose, its job is to let your system adjust to the medicine before the prescriber increases to doses where the therapeutic effect becomes meaningful. From there, the schedule moves through 5, 7.5, 10, 12.5 and 15mg, each step typically taken for around four weeks before the next is considered. The prescriber makes that call, not the patient.

At the 15mg maintenance dose, SURMOUNT-1 (a 72-week randomised trial published in the New England Journal of Medicine) found average body-weight reductions of around 20 to 21 percent among adults with obesity. Those are large effects by any clinical standard, produced within the licensed 15mg ceiling. The idea that you'd need to go further, to a hypothetical 30mg, misreads what the evidence shows. The ceiling is 15mg because that is where the benefit-risk profile was established and approved, not because the researchers ran out of ideas.

For a broader picture of how tirzepatide works as a dual GIP and GLP-1 receptor agonist, the NHS medicines page for tirzepatide sets out the mechanism and the licensed dose range clearly. It is worth reading before any consultation.

The decision in front of you: licensed treatment or an unlicensed product

If you landed on this page because you were weighing up whether to source a 30mg preparation, that is the decision worth sitting with. On one side: a licensed medicine, manufactured under pharmaceutical-grade conditions, dispensed by a pharmacy you can check on the GPhC register, reviewed by a named prescriber, with a known safety profile and a supply chain the MHRA can audit. On the other: a product with none of those assurances.

The Mounjaro treatment page sets out exactly what licensed treatment involves, eligibility, the consultation process, what a GPhC-registered pharmacy does before dispensing. For those curious about cost, the Mounjaro pricing page explains what a legitimate private prescription typically includes and how the market sits following Eli Lilly's 2025 price adjustment.

There is also a specific group of people researching 30mg tirzepatide because they've encountered it described as a research chemical or peptide product. The peptide tirzepatide context is worth understanding separately, the short version is that research-grade peptides are not manufactured for human injection and are not subject to medicines regulation. That is not a technicality; it is a safety distinction.

What the right next step looks like in practice

For most people reading this, the practical path forward is straightforward. A consultation with a prescriber who knows the licensed options means you get an honest assessment of whether Mounjaro (at the doses that actually exist) suits your situation, or whether another licensed treatment makes more sense. That might be a different weight-loss medicine altogether, depending on your health picture.

At nume, every consultation is read by a GPhC-registered Independent Prescriber the same day. There are no algorithms making clinical calls. If you order before midday on a working day and your consultation is approved, treatment is dispatched the same day and arrives with DPD the following working day, tracked, in plain packaging. Our clinical team is there if you have questions before or after. The FAQs page covers the questions that come up most, and our support team is available seven days a week.

If you'd like a prescriber to look at your situation properly, the place to start is a free consultation. Speak to our prescribers, it costs nothing and gives you a straight answer.